What is William Blair's Estimate for Qiagen FY2024 Earnings?

Qiagen (NYSE:QGEN - Free Report) - William Blair upped their FY2024 earnings estimates for Qiagen in a research report issued to clients and investors on Monday, November 11th. William Blair analyst A. Brackmann now expects that the company will post earnings of $2.17 per share for the year, up from their prior estimate of $2.14. The consensus estimate for Qiagen's current full-year earnings is $2.18 per share. William Blair also issued estimates for Qiagen's Q2 2025 earnings at $0.57 EPS, Q3 2025 earnings at $0.58 EPS and FY2025 earnings at $2.26 EPS.

Several other equities research analysts have also recently weighed in on the stock. Robert W. Baird upped their price objective on shares of Qiagen from $49.00 to $52.00 and gave the stock an "outperform" rating in a research report on Friday, August 2nd. Hsbc Global Res upgraded shares of Qiagen to a "hold" rating in a research report on Thursday, October 17th. Finally, HSBC downgraded Qiagen from a "buy" rating to a "hold" rating and set a $49.00 target price on the stock. in a report on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, Qiagen has a consensus rating of "Moderate Buy" and a consensus target price of $50.88.

Qiagen Price Performance

Qiagen stock traded down $0.60 during mid-day trading on Wednesday, reaching $42.63. 803,279 shares of the company were exchanged, compared to its average volume of 1,166,503. The company has a fifty day simple moving average of $43.99 and a 200-day simple moving average of $43.78. The firm has a market cap of $9.73 billion, a PE ratio of 109.36, a PEG ratio of 3.29 and a beta of 0.41. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.17 and a quick ratio of 1.46. Qiagen has a 12 month low of $39.03 and a 12 month high of $47.44.

Hedge Funds Weigh In On Qiagen

Institutional investors and hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC grew its holdings in shares of Qiagen by 806.5% during the third quarter. GAMMA Investing LLC now owns 562 shares of the company's stock worth $26,000 after purchasing an additional 500 shares during the last quarter. Toronto Dominion Bank acquired a new stake in Qiagen during the 2nd quarter worth approximately $27,000. Massmutual Trust Co. FSB ADV grew its holdings in Qiagen by 39.8% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company's stock worth $39,000 after acquiring an additional 243 shares during the last quarter. CWM LLC grew its holdings in Qiagen by 12.0% during the 2nd quarter. CWM LLC now owns 2,505 shares of the company's stock worth $103,000 after acquiring an additional 269 shares during the last quarter. Finally, Headlands Technologies LLC increased its position in Qiagen by 396.6% in the 2nd quarter. Headlands Technologies LLC now owns 2,741 shares of the company's stock valued at $113,000 after acquiring an additional 2,189 shares during the period. Institutional investors and hedge funds own 70.00% of the company's stock.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.